09:30 AM EST - Eupraxia Pharmaceuticals Inc. : Today announced additional positive clinical data from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading unchanged at $5.33.
